GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.93 $1.65 Wednesday, 17th Apr 2024 ADAP stock ended at $0.99. This is 4.17% less than the trading day before Tuesday, 16th Apr 2024. During the day the stock fluctuated 12.35% from a day low at $0.93 to a day high of $1.05.
90 days $0.676 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2022-03-14 $1.83 $1.90 $1.77 $1.82 1 046 600
2022-03-11 $1.90 $1.93 $1.81 $1.82 1 135 100
2022-03-10 $1.94 $1.94 $1.86 $1.89 825 700
2022-03-09 $2.00 $2.04 $1.92 $1.94 1 735 900
2022-03-08 $1.99 $2.03 $1.90 $1.95 2 753 900
2022-03-07 $2.08 $2.16 $1.90 $1.95 7 938 500
2022-03-04 $2.14 $2.19 $2.02 $2.05 1 253 900
2022-03-03 $2.35 $2.36 $2.16 $2.19 3 319 300
2022-03-02 $2.40 $2.45 $2.28 $2.32 2 034 400
2022-03-01 $2.60 $2.62 $2.39 $2.41 3 378 200
2022-02-28 $2.64 $2.77 $2.58 $2.60 641 200
2022-02-25 $2.73 $2.74 $2.60 $2.69 375 100
2022-02-24 $2.45 $2.74 $2.42 $2.69 788 300
2022-02-23 $2.82 $2.83 $2.65 $2.67 320 100
2022-02-22 $2.78 $2.93 $2.76 $2.79 471 400
2022-02-18 $2.98 $3.00 $2.84 $2.87 473 800
2022-02-17 $3.09 $3.09 $2.97 $3.00 1 099 900
2022-02-16 $3.18 $3.25 $3.10 $3.10 766 500
2022-02-15 $3.15 $3.20 $3.09 $3.17 529 800
2022-02-14 $3.07 $3.14 $3.04 $3.10 631 700
2022-02-11 $3.14 $3.19 $3.02 $3.06 509 300
2022-02-10 $3.12 $3.32 $3.05 $3.13 675 100
2022-02-09 $3.08 $3.24 $3.08 $3.18 498 900
2022-02-08 $3.06 $3.10 $2.96 $3.04 357 100
2022-02-07 $2.86 $3.14 $2.86 $3.07 854 500
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT